For <i>EGFR</i>-mutant NSCLC, sequential development of tyrosine kinase inhibitors (TKIs) from first- to third-generation agents-culminating in osimertinib-has markedly improved survival. Here, EGFR is linked to non-small cell lung carcinoma.